Comparative Pharmacology
Head-to-head clinical analysis: MAXALT versus MAXALT MLT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXALT versus MAXALT MLT.
MAXALT vs MAXALT-MLT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective serotonin 5-HT1B/1D receptor agonist; causes vasoconstriction of cranial arteries and inhibits trigeminal nerve signaling.
Selective 5-HT1B/1D receptor agonist; causes vasoconstriction of intracranial arteries and inhibits trigeminal nerve activation.
5 mg or 10 mg orally at onset of migraine; maximum 30 mg in 24 hours (two doses with at least 2 hours between them).
10 mg orally as a single dose; maximum 30 mg in 24 hours. Administer at onset of migraine; do not use for prophylaxis.
None Documented
None Documented
2-3 hours in plasma; clinical effect correlates with distribution to CNS rather than plasma half-life.
Terminal elimination half-life of approximately 2-3 hours; clinical context: short half-life supports acute migraine treatment with rapid offset.
Renal (60% as unchanged drug and metabolites) and fecal (40% primarily as metabolites).
Primarily hepatic metabolism; ~14% excreted unchanged in urine, ~76% as metabolites in feces via bile, total renal excretion of parent and metabolites ~40%.
Category C
Category C
Antimigraine Agent
Antimigraine Agent